Oramed Pharmaceuticals (NASDAQCM:ORMP) is developing proprietary Protein Oral Delivery (POD™) technology for the delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently approaching a Phase 2b multi-center trial under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
To review the safety data on Oramed's Phase 2a FDA trial on ORMD-0801 on patients with type 2 diabetes, click here.
Oramed in the News
January 30th, 2014: Bloomberg - Oral Diabetes Medicine Shows Promist in Study of Oramed Pill
January 30th, 2014: Reuters - Israel's Oramed says oral insulin capsule trial a success
For more of Oramed in the news, please click here.